LYEL
Lyell Immunopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$405.20M
P/E Ratio
—
EPS
$-13.62
Beta
-0.06
52W High
$45.00
52W Low
$7.65
50-Day MA
$21.13
200-Day MA
$20.42
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
Fundamentals
| Revenue (TTM) | 31,000 |
| Gross Profit (TTM) | 31,000 |
| EBITDA | $-174.75M |
| Operating Margin | -2213050.00% |
| Return on Equity | -80.80% |
| Return on Assets | -29.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $12.88 |
| Price-to-Book | 1.47 |
| Price-to-Sales (TTM) | 13070.85 |
| EV/Revenue | 6063.77 |
| EV/EBITDA | 0.25 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -71.40% |
| Shares Outstanding | $23.33M |
| Float | $10.39M |
| % Insiders | 35.44% |
| % Institutions | 58.31% |
Historical Volatility
HV 10-Day
63.36%
HV 20-Day
57.13%
HV 30-Day
65.59%
HV 60-Day
72.93%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($37.17 target)
2
Strong Buy3
Buy1
Strong SellMore HEALTHCARE Stocks
Data last updated: 5/23/2026